Rescue of dystrophic skeletal muscle by PGC-1α involves a fast to slow fiber type shift in the mdx mouse

N/ACitations
Citations of this article
146Readers
Mendeley users who have this article in their library.

Abstract

Increased utrophin expression is known to reduce pathology in dystrophin-deficient skeletal muscles. Transgenic over-expression of PGC-1α has been shown to increase levels of utrophin mRNA and improve the histology of mdx muscles. Other reports have shown that PGC-1α signaling can lead to increased oxidative capacity and a fast to slow fiber type shift. Given that it has been shown that slow fibers produce and maintain more utrophin than fast skeletal muscle fibers, we hypothesized that over-expression of PGC-1α in post-natal mdx mice would increase utrophin levels via a fiber type shift, resulting in more slow, oxidative fibers that are also more resistant to contraction-induced damage. To test this hypothesis, neonatal mdx mice were injected with recombinant adeno-associated virus (AAV) driving expression of PGC-1α. PGC-1α over-expression resulted in increased utrophin and type I myosin heavy chain expression as well as elevated mitochondrial protein expression. Muscles were shown to be more resistant to contraction-induced damage and more fatigue resistant. Sirt-1 was increased while p38 activation and NRF-1 were reduced in PGC-1α over-expressing muscle when compared to control. We also evaluated if the use a pharmacological PGC-1α pathway activator, resveratrol, could drive the same physiological changes. Resveratrol administration (100 mg/kg/day) resulted in improved fatigue resistance, but did not achieve significant increases in utrophin expression. These data suggest that the PGC-1α pathway is a potential target for therapeutic intervention in dystrophic skeletal muscle. © 2012 Selsby et al.

Figures

  • Table 1. PGC-1a induced changes in muscle mass.
  • Figure 1. Virally-mediated gene transfer. Six weeks following PGC1a gene delivery total (PGC-1a) and viral (V-PGC-1a) expression was increased in treated limbs compared to untreated limbs (n = 6/group). * indicates p,0.05. doi:10.1371/journal.pone.0030063.g001
  • Table 2. PGC-1a induced changes in muscle function.
  • Figure 2. Relative force reduction in 6 wk old EDL’s following lengthening contractions. PGC-1a over-expressing limbs were better able to maintain force during lengthening contractions when compared to control limbs (n = 13/group). Data from age matched C57 animals is included for reference purposes. * indicates p,0.05. Con – contraction. doi:10.1371/journal.pone.0030063.g002
  • Figure 3. PGC-1a protects against muscle fatigue. Muscle fatigue curves in the soleus (n = 6/group) and EDL (n = 7/group) (A) during 10 minutes of a fatigue protocol where muscles are contracted every second for 10 minutes. Force of the final contraction (B) was significantly higher in the soleus and EDL muscles over-expressing PGC-1a when compared to control muscle. * indicates p,0.05. doi:10.1371/journal.pone.0030063.g003
  • Figure 4. PGC-1a over-expression reduces disease-related muscle injury. 106micrographs of six week old soleus muscles following H and E staining (A and B). (C) The total areas of necrotic, H&E negative, or regenerating cells were quantified and is expressed as a percent of the total soleus area. In addition, laminin was detected with a fluorescently labeled antibody (not shown) in order to determine central nucleation. (D) PGC-1a caused a reduction in central nucleation. N = 5/group; * indicates p,0.05. doi:10.1371/journal.pone.0030063.g004
  • Figure 5. Protein expression following 6 weeks of PGC-1a overexpression. Slow genes are shown in black (utrophin – A, slow myosin heavy chain – B) oxidative genes are shown in gray (cytochrome C – C, uncoupling protein-1 – D, complex IV subunit IV – E, myoglobin – F, Hsp 60 – G), pathway genes are shown in white (Sirt-1 – H, nuclear respiratory factor -1 – I, p38 – J, phospho-p38 – K), and controls have diagonal lines (Actin – L, Troponin – M, Spectrin – N). Relative change compared to control limbs (n = 6/group) (O). * indicates p,0.05 compared to control limbs. doi:10.1371/journal.pone.0030063.g005
  • Figure 6. Myosin fiber type distribution in treated and control soleus muscles. Histological sections of soleus (106) were exposed to an antibody against the slow isoform of myosin heavy chain (A). A C57 (healthy) section is included as reference (Left). The control limb (middle) shows moderate type I content. The corresponding injected limb (Right) clearly has an elevation in type I content. In serial sections, we also evaluated type II myosin heavy chain content (B). A C57 (healthy) section is included for reference (Left). The control limb (middle) shows high levels of type II expression. PGC-1a caused a reduced expression of type II fibers (Right). The absolute fiber numbers from each section expressing type I and II fibers were counted and recorded (C). PGC-1a caused a shift toward type I fibers and away from type II fibers. These were then made relative to total fiber number (D). Once again, a type I shift is observed. N = 9/group; * indicates p,0.05. doi:10.1371/journal.pone.0030063.g006

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Selsby, J. T., Morine, K. J., Pendrak, K., Barton, E. R., & Sweeney, H. L. (2012). Rescue of dystrophic skeletal muscle by PGC-1α involves a fast to slow fiber type shift in the mdx mouse. PLoS ONE, 7(1). https://doi.org/10.1371/journal.pone.0030063

Readers over time

‘12‘13‘14‘15‘16‘17‘18‘19‘20‘21‘22‘23‘24‘2506121824

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 46

51%

Researcher 28

31%

Professor / Associate Prof. 15

16%

Lecturer / Post doc 2

2%

Readers' Discipline

Tooltip

Agricultural and Biological Sciences 36

40%

Biochemistry, Genetics and Molecular Bi... 34

38%

Medicine and Dentistry 13

15%

Pharmacology, Toxicology and Pharmaceut... 6

7%

Save time finding and organizing research with Mendeley

Sign up for free
0